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Immunization by the SF162gp140 or the ΔV2gp140 HIV-1 envelope proteins results in the generation of strong homologous neutralizing
antibodies (NAbs) that offer similar degree of protection from disease-development to macaques challenged with homologous virus. These two
immunogens elicit weak cross-reactive NAbs and their effectiveness against heterologous challenge is currently unknown. To examine this issue,
we immunized macaques with SIVGag p55 and either the SF162gp140 or the ΔV2gp140 and challenged them intravenously with SHIV-89.6P.
All animals became infected but previous immunization with SF162gp140 accelerated the development of anti-SHIV89.6P neutralizing antibody
responses following infection. ΔV2gp140 is derived from SF162gp140 following the deletion of 30 amino acids and one N-linked glycosylation
site from the V2 loop. Our results suggest that even small differences in HIV Envelope immunogen structure can affect the neutralizing antibody
responses generated following infection.
© 2006 Elsevier Inc. All rights reserved.Keywords: HIV Env gp140; HIV-1SF162; SHIV89.6P; Neutralizing antibodies; T cell responsesIntroduction
Several groups reported on the development of immuniza-
tion protocols, based on DNA or viral vectors, that elicit potent
cell-mediated anti-viral (SHIVor SIV) responses in non-human
primates (Amara et al., 2001; Barouch et al., 2000; Casimiro et
al., 2004; Patterson et al., 2002; Shiver et al., 2002). In most
cases, but not always (Horton et al., 2002; Vogel et al., 2001),
these responses allow for the long-term effective control of viral
replication, prevent the loss of CD4+ T lymphocytes and delay
or prevent the development of AIDS.⁎ Corresponding author. Seattle Biomedical Research Institute, 307 Westlake
Avenue North, Seattle, WA 98109, USA. Fax: +1 206 256 7229.
E-mail address: leo.stamatatos@sbri.org (L. Stamatatos).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.01.043Neutralizing antibodies (NAbs) also participate in the control
of viral (SIV or SHIV) replication in non-human primates
(Amara et al., 2001; Barouch et al., 2001; Buckner et al., 2004;
Johnson et al., 2003; Seth et al., 2000). In rare cases, vaccine-
elicited NAbs offer protection from infection by viruses that
express envelope glycoproteins that are homologous or highly
related to the immunogens (Hu et al., 1992; Polacino et al.,
1999a, 1999b, 1999c). However, currently available HIV
envelope immunogens and immunization methodologies and
protocols, are infective in eliciting potent and long-lasting
cross-reactive neutralizing antibody responses, which are
required for protection from viruses that express envelope
glycoproteins that are heterologous to the immunogens.
The current unavailability of immunogens that would elicit
sterilizing immunity against diverse challenge HIV viruses
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and immunization protocols that aim at the development of
both cell-mediated anti-viral responses and NAbs, that would
limit the initial number of infected cells, prevent the rapid and
wide dissemination of infection to secondary sites, and
hopefully allow the host the opportunity to develop anti-
viral responses capable of controlling infection for very long
periods of time.
We previously reported that immunization of macaques with
oligomeric HIV-1 gp140 envelope protein immunogens
(SF162gp140 or ΔV2gp140), using the ‘DNA-prime plus
protein-boost’ immunization methodology, results in the
generation of potent homologous NAbs (Barnett et al., 2001).
The presence of such antibodies reduces the replication of a
SHIV virus expressing a homologous envelope (SHIVSF162P4)
during acute infection, even in the absence of detectable CD8+
cells. Importantly, viral replication was effectively controlled
during the chronic phase of infection, so that the animals
remained avaremic and healthy for extended periods of time.
SHIVSF162P4 was isolated during serial in vivo passage of
SHIVSF162 (Harouse et al., 1999; Luciw et al., 1995) and
expresses an envelope that is very similar to HIV-1 SF162. Like
HIV-1 SF162, SHIVSF162P4 utilizes CD4 and CCR5 for entry
(Harouse et al., 1999).
In the present study, we examined whether the above-
mentioned SF162gp140 and ΔV2gp140 immunogens would
offer the same degree of protection to macaques challenged with
a virus that expresses a heterologous envelope glycoprotein.
TheΔV2gp140 protein is derived from the SF162gp140 protein
following the elimination of 30 amino acids and one N-linked
glycosylation site from the V2 loop (Stamatatos and Cheng-
Mayer, 1998; Stamatatos et al., 2000). Because we previously
reported that ΔV2gp140 was more effective than SF162gp140
in eliciting cross-reactive NAbs (albeit at low titers) (Barnett et
al., 2001), we expected that immunization with ΔV2gp140
would offer better protection against heterologous challenge
than immunization with SF162gp140. We included in our
vaccine preparation the SIVGag p55 antigen because we wanted
to elicit as broad as possible cell-mediated anti-SHIV responses.
During the DNA phase of immunization very weak anti-Env
antibody responses were elicited. Interestingly, these responses
were gp120 but not gp41 directed. In contrast, both anti-gp120
and anti-gp41 antibodies were developed following the
subsequent immunization with recombinant gp140 proteins. It
appears therefore that gp41 epitopes are not as immunogenic as
gp120 epitopes when gp140 is expressed by DNA. Following
recombinant gp140 immunization, both the SF162gp140 and
the ΔV2gp140 immunized animals developed both gp120 and
gp41 binding antibodies and strong homologous NAbs. Strong
neutralizing antibodies were also developed against laboratory-
adapted HIV-1 isolates. However, weak and sporadic cross-
reactive NAbs were developed against heterologous primary
HIV-1 isolates. Following immunization, the vaccinated, as well
as mock vaccinated control, animals were exposed intrave-
nously to SHIV-89.6P whose envelope displays 81.7% and
84.9% amino acid homology within the gp120 and gp41
subunits, respectively, of our immunogens. SHIV89.6P wasisolated during serial in vivo passage of SHIV89.6 (Reimann et
al., 1996), and is highly pathogenic. Its envelope uses CD4 and
either CXCR4 or CCR5 (Zhang et al., 2000). All animals
became infected, but those previously immunized with
SF162gp140 were more effective in eliciting anti-SHIV89.6P
NAbs following infection.
Results
Vaccine elicited immune responses
Anti-HIV Envelope binding antibody responses
Weak and transient binding anti-HIV Env antibody
responses were elicited during the DNA phase of immunization
(Fig. 1A). All six SF162gp140-animals, but only three of the six
ΔV2gp140-immunized animals, generated homologous anti-
gp120 antibodies during this period. Antibodies against HxB2
gp41 or against the 89.6P gp140 (KB9 clone) envelope
glycoproteins were undetectable in all vaccinees during the
DNA phase of immunization.
Following the first immunization with DNA and recombi-
nant gp140 envelope (we term this immunization step as
recombinant protein boost, for simplicity), a significant increase
of homologous anti-gp120 binding antibody titers in all six
SF162gp140-immunized macaques was recorded. At this stage,
five out of the six ΔV2gp140-immunized macaques had
detectable homologous anti-gp120 binding antibodies. Anti-
gp120 antibodies were detectable during the following 20
weeks of observation in those eleven animals, although their
titers gradually decreased in 7 of these 11 responders. Anti-gp41
antibodies were also detectable in 4/6 and 3/6 SF162gp140- and
ΔV2gp140, respectively, immunized animals following recom-
binant gp140 protein immunization. In contrast to the
homologous anti-gp120 antibodies, the titers of anti-gp41
antibodies decreased to undetectable levels within 5–10
weeks following this booster immunization. It should be
noted that in contrast to the gp120 protein, the gp41 used in
these assays was derived from the heterologous HXB2 virus.
There is 91% homology between the SF162 and HXB2 gp41 (in
the gp41 portion used here). Anti-89.6P gp140 Env antibodies
were also developed in 4/6 and 3/6 SF162gp140 and
ΔV2gp140, respectively immunized animals. Similarly to
what we observed with the anti-gp41 antibodies, the anti-
89.6P gp140 antibody titers decreased to undetectable levels
shortly following immunization. There is 81% homology
between the 89.6P and HXB2 gp41 (in the portion used here).
Following the second DNA and recombinant envelope gp140
protein immunization, homologous anti-gp120 antibodies were
detectable in all SF162gp140 and ΔV2gp140 immunized
animals. All six SF162gp140 immunized animals developed
anti-gp41 antibodies following the second recombinant enve-
lope immunization and 4/6 developed antibodies against 89.6P
gp140. In contrast, 5/6 animals immunized with ΔV2gp140
developed anti-gp41 antibodies, but all 6 developed anti-
89.6Pgp140 antibodies. Overall, the titers of anti-gp41 and
anti-89.6Pgp140 binding antibodies were lower than those
against the homologous SF162gp120 in both immunized groups.
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High titers of NAbs against SHIVSF162P4, a virus that
expresses an envelope glycoprotein that is homologous to HIV-1 SF162, were developed in all immunized animals following
the first immunization with the recombinant gp140 envelope
protein (at week 32) (Fig. 1B). The IC50 neutralization titers
Table 1
Summary of anti-viral immune responses elicited during vaccination






32 w 52 w 14 w 52 w
SF162gp140 A02189 1700 >3000 583 1290
A02188 3000 >3000 540 535
A02186 (+) 370 410 58 413
A02179 (+) >3000 >3000 131 758
O2193 (+) 300 1800 495 221
A02177 (+) 3000 410 1535 1385
ΔV2gp140 A02185 750 2000 362 948
A02183 650 760 446 1316
O2184 850 445 596 867
O2187 850 600 460 386
A02311 2200 1700 545 443
A02178 2000 1000 102 331
14 w: 1 month post 3rd DNA immunization; 32 and 52w: 2 weeks following the
1st or 2 weeks following 2nd recombinant Env gp140 protein immunizations,
respectively.
(+): Mamu-A*01+ animals.
a Sum of Gag and Env-specific IFN-γ secreting cells.
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group and between 1:700 and 1:3000 in the ΔV2gp140
immunized group. The 2nd recombinant envelope immuniza-
tion resulted in an enhancement of the homologous NAbs titers
in 4/6 SF162gp140-immunized animals (see Table 1). In one
case however (animal A02177), the titers actually decreased as
compared to those recorded following the first recombinant
gp140 Env immunization. In contrast, the second immunization
with ΔV2gp140 did not result in an increase of homologous
NAbs titers, in fact in some cases (animals A02178, A02311,
and O2184) the titers decreased. Overall, there was not
statistically significant difference in the titers of homologous
NAbs elicited by the SF162gp140 and ΔV2gp140 immuno-
gens. Also, the titers of NAbs did not always correlate with the
titers of homologous binding antibody titers. These data suggest
that the two immunogens elicit in part antibodies against non-
neutralizing epitopes or antibodies against neutralizing epitopes
that are not exposed on the virion-associated envelope. NAbs
against SHIV-89.6P were not readily detectable with the
neutralization assay used here in sera collected either after the
first or second recombinant envelope immunizations (data not
shown), even though binding anti-89.6 Env antibodies were
present (Fig. 1A). However, the anti-89.6P Env antibody titers
were weak and most likely insufficient to mediate neutralization
of SHIV89.6P.
We also examined whether sera collected from the SF162
and ΔV2 immunized animals possessed neutralizing activity
against several heterologous HIV-1 isolates (Table 2). We tested
both laboratory-adapted isolates (MN and Nl4-3) and several
primary isolates (Li et al., 2005) (Table 2 and data not shown).
As a negative control for these assays we used MuLV envelope
expressing virions (Binley et al., 2004). All 12 animals elicited
very potent NAbs against MN. Also, 5/6 ΔV2-immunized
animals and 4/6 SF162-immunized animals elicited potent
NAbs against NL4-3. Weaker neutralizing antibody responses
were elicited against only some of the primary HIV-1 isolates
tested. Virus expressing the primary envelope 7165 was
susceptible to neutralization by most sera tested (6/6 from the
SF162 immunized animals and 3/6 from the ΔV2 immunized
animals). Similarly, 4/6 animals immunized with SF162 orΔV2
elicited NAbs against virions expressing the 3988 envelope.
However, the remaining viruses were either resistant to
neutralization to all sera or only a minority (one or two) of
animals per group elicited NAbs against them. Overall
therefore, these results indicate that the SF162 gp140 and
ΔV2 gp140 proteins are capable of eliciting NAbs against a
certain heterologous primary HIV-1 isolates but the breadth and
potency of these responses is narrow (Barnett et al., 2001;
Srivastava et al., 2003b).Fig. 1. Development of anti-viral immune responses during vaccination. (A) Vaccin
HXB2 gp41, and SHIV-89.6P gp140. Black arrows indicate immunizations with DN
recombinant HIV Env. Top panels: animals immunized with SIVGag and SF162g
Homologous neutralizing antibody responses (against SHIVSF162P4) at week 32 (2 w
weeks following the second immunization with recombinant Env). Symbols are the s
(as indicated by the secretion of IFN-γ upon stimulation of PBMCs with Env or Ga
weeks after the last immunization with recombinant HIV Env (i.e., at the day of virCell-mediated anti-viral responses
PBMC-based IFN-γ ELISPOT assays were performed to
assess cellular immune responses during the vaccination (Fig.
1C, left panel). As expected, the mock-immunized animals
had undetectable anti-viral responses during that period (data
not shown). Both the SF162gp140 and the ΔV2gp140
immunized animals developed potent anti-HIV Env- and
anti-SIV Gag-specific cellular responses after the 3rd DNA
immunization. In most animals, the anti-Gag-specific
responses were more potent than the anti-HIV Env responses.
The two subsequent immunizations with recombinant HIV
Env enhanced the anti-Env cellular responses (Fig. 1C, right
panel). One month following the third DNA immunization
(week 14), the mean total vaccine-elicited ELISPOT responses
to both Env and Gag protein were 361 ± 247 SFC in the
SF162gp140 group (excluding animal A02177), and
419 ± 175 in ΔV2gp140 group (Table 1). Two weeks after
the second recombinant envelope protein immunization (week
52, which was also the day of challenge) total IFN-γ
ELISPOT responses were 643 ± 411 and 715 ± 392 SFC in
the SF162gp140 (excluding animal A02177) and ΔV2gp140
groups, respectively. No significant differences were recorded
between these two immunization groups in the development
of anti-HIV Env and anti-SIV-Gag cellular responses. Animal
A02177 (in the SF162gp140 group) had an unusually high
Gag-specific cellular response during the DNA phase ofe-elicited binding antibodies responses were determined against SF162 gp120,
A vectors alone and white arrows indicate immunizations with DNAvectors and
p140; bottom panels: animals immunized with SIVGag and ΔV2gp140. (B)
eeks following the first immunization with recombinant Env) and week 52 (2
ame as in panel A. (C) Anti-HIV Env and anti-SIV Gag cell-mediated responses
g peptides), 1 month following the third DNA immunization (left panel) and 2
al-challenge).
Table 2
Neutralization of heterologous HIV-1 isolates
Animals SF162-gp140 immunogen
3988 6101 AR29 QH0515 QH0692 TRO SS1196 BG1168 6535 7165 PVO MN NL43 MuLV
A02188 10 (–) (–) 10 (–) (–) 10 (–) (–) 10 (–) 1576 141 (–)
A02189 15 10 (–) (–) (–) (–) (–) (–) (–) 10 (–) 532 136 (–)
A02186 10 (–) (–) (–) (–) (–) (–) (–) (–) 10 (–) 549 (–) (–)
A02179 10 (–) (–) (–) (–) (–) (–) (–) 20 10 (–) 1574 316 (–)
A02177 (–) (–) (–) (–) 10 (–) 10 (–) 10 10 (–) 894 237 (–)
A02193 (–) (–) (–) (–) (–) (–) (–) (–) (–) 10 (–) 277 (–) (–)
Animals ΔV2-gp140 immunogen
3988 6101 AR29 QH0515 QH0692 TRO SS1168 BG1168 6535 7165 PVO MN NL43 MuLV
A02183 10 (–) (–) (–) (–) (–) (–) (–) (–) (–) (–) 344 118 (–)
A02184 10 20 (–) (–) (–) (–) (–) (–) (–) 10 (–) 540 174 (–)
A02185 20 20 (–) 10 (–) 20 10 (–) (–) 10 (–) 4315 1150 (–)
A02178 (–) (–) (–) (–) (–) (–) (–) (–) 10 10 (–) 1711 507 (–)
A02187 10 (–) (–) (–) (–) (–) (–) (–) (–) (–) (–) 425 (–) (–)
A02311 (–) (–) (–) (–) (–) (–) (–) (–) 10 (–) (–) 1128 226 (–)
Values indicate the serum dilution that resulted in 50% neutralization. (–): 50% neutralization was not recorded at the lowest serum dilution (1:10).
280 R. Xu et al. / Virology 349 (2006) 276–289immunization. Therefore we did not include this animal in the
above calculations.
Taken together, the above results indicate that both antibody
and cellular responses were elicited in both groups of
immunized animals, however, no significant differences were
obvious between the two immunized groups in the elicitation of
neutralizing antibodies and cell-mediated responses.
SHIV-89.6P -challenge
The animals were challenged intravenously with 100TCID50
of cell-free SHIV89.6P on week 52 (2 weeks following second
HIV gp140 envelope protein immunization). All animals
became infected (Fig. 2).
Viral load levels during acute and chronic infection
Viral replication was assessed by quantitating plasma viral
RNA levels by QC-PCR (limit of detection 50 RNA copies per
ml) during the first 28 weeks and by a b-DNA-based assay
(limit of detection 125 copies per ml) after that point (Fig. 2A).
The medians of peak viral loads during acute infection (2 weeks
post-challenge) in the three groups of monkeys were 5.6 × 106
(mock-immunized), 1.45 × 106 (SF162gp140-immunized) and
4.4 × 106 (ΔV2gp140-immunized).
Two mock-immunized animals A02180 and A00051, had
decreasing plasma viremia during chronic infection, and the
latter animal was aviremic starting at week 20 post-infection
(Fig. 2A). In the remaining three animals of this group (A02190,
A02194 and O2181) plasma viremia levels remained high (over
105 RNA copies per ml) and increased even further over time.
These three animals developed AIDS and were euthanized at
weeks 22, 28 and 44 post-challenge. In the SF162gp140-
immunized group, four animals (A02188, A02177, O2193, and
A02189) had plasma viremia levels below 103 RNA copies per
ml (two of them had undetectable plasma viremia, animals
A02189 and O2193) during the chronic phase of infection. In
contrast, only one (animal O2184) of the ΔV2gp140-immu-nized animals had sustained low (below 103 RNA copies per
ml) levels of plasma viremia during chronic infection. One of
the ΔV2gp140 immunized monkeys, A02185, was euthanized
4 weeks post challenge and a second animal of this group,
A02183, was euthanized 20 weeks post-infection, because they
developed AIDS. None of the ΔV2gp140-immunized animals
was consistently aviremic during the chronic phase of infection.
CD4+ T lymphocyte numbers
A profound and sustained loss of CD4+ T lymphocytes was
observed within 3 weeks post-challenge in the three mock
immunized animals, which had sustained high plasma viremia
(A02194, A02190 and O2181) (Fig. 2B). In the other two
animals of this group (A00051 and A02180), an initial drop in
CD4+ T cell numbers was recorded during the first 4 weeks of
infection, but subsequently, these numbers gradually increased
and stabilized over time. In contrast, a blunting of CD4+ T-
lymphocyte depletion was recorded in four of the six
SF162gp140 monkeys. This decrease in CD4+ T cell loss was
statistically significant (Mann–Whitney U test and 95%
confidence interval; P: 0.0159). In the fifth animal (A02189)
the initial drop in CD4+ T lymphocyte numbers occurred, but
the numbers eventually increased over time. The sixth animal of
this group (A02186) displayed a significant but sustained loss of
CD4+ T lymphocytes. In one of the ΔV2gp140 animals
(O2184), a blunting of the CD4+ T lymphocyte loss was
recorded, while in two others (A02178 and O2187) a significant
initial loss of CD4+ T lymphocyte numbers was recorded, but
subsequently these numbers increased and stabilized over time.
Anti-viral immune responses after infection
Binding anti-Env antibody responses
Within 4 weeks after challenge, the titers of binding anti-
89.6P Env antibodies increased approximately 10 fold in both
SF162gp140 and ΔV2gp140 immunized animals (Fig. 3A).
Even the two animals in the SF162gp140 immunized group,
Fig. 2. Plasma viremia and peripheral CD4+ T lymphocyte numbers. (A) RNA copy numbers were determined by QC-PCR (limit of detection 50 RNA copies per ml)
for the first 28 weeks and by bDNA-based assay (limit of detection 125 copies per ml) after that point. (†) Indicates the time of death of the animals. Mamu-A*01+
animals are indicated with (+). (B) Percentage of CD4+ T lymphocytes in peripheral blood.
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during immunization (animals A02177 and O2193), developed
such antibodies following infection. During the subsequent 20
weeks, the anti-89.6P Env antibody titers remained at high
levels in most animals, or transiently decreased in animals
A02111, A02183, and O2184 of the ΔV2gp140-immunized
group, and animal O2193 in the SF162gp140-immunized
group. However, the titers gradually increased between weeks
20 and 52 (end of the observation period) in most animals. The
exception being animal A02183 in the ΔV2gp140-immunized
group, who displayed continuously decreasing anti-89.6P Env
binding antibody titers and who eventually developed AIDS as
discussed above. The two mock-immunized animals that did not
develop AIDS had low plasma viremia, and a transient loss of
their CD4+ T lymphocyte numbers were the only animals of this
group that developed anti-89.6P Env antibodies (animals
A02180 and A00051).
A very similar pattern to the anti-89.6P Env antibody
responses was recorded with the anti-gp41 antibody responses
following challenge, with A02183 (ΔV2gp140-immunized
group) showing decreasing anti-gp41 antibodies as it pro-
gressed to disease.
Following SHIV89.6P-infection in all 12 immunized animals,
irrespective of the HIV Env gp140 immunogen they wereimmunized with, the anti-SF162gp120 antibodies remained
high throughout the period of observation. Two of the mock-
immunized animals that developed anti 89.6P Env and anti-
gp41 antibodies following infection (animals A02180 and
A00051) also developed anti-SF162gp120 binding antibodies.
Interestingly, a third animal in this group, O2181 also developed
transient and weak anti-SF162gp120 antibodies (but not anti
89.6P or anti-gp41 antibodies).
Anti-SHIV89.6P neutralizing antibodies
8 weeks post-infection, anti-SHIV-89.6P NAbs were detect-
able in the two mock immunized animals (A02180 and
A00051) that were able to control infection (Fig. 3B).
Interestingly, in these two animals, anti-SHIV-89.6P NAbs
were detected earlier than the anti-89.6P gp140 binding
antibodies (Fig. 3A). Differences in the relative sensitivity of
the neutralization and ELISA assays used here, could be the
cause of this unexpected result. Also, the use of the TZM-bl cell
line to screen for the development of NAbs could result in the
detection of NAbs with particular epitope-specificities (Binley
et al., 2004) that are not readily detected with the ELISA assays.
Finally, early neutralization of SHIV89.6P could be primarily due
to the generation of NAbs that bind to CD4-induced epitopes.
Such antibodies would not be readily detectable by ELISA.
Fig. 3. Antibodies responses following post SHIV89.6P challenge. (A) Relative end-point ELISA binding antibody titers against SF162 gp120, HXB2 gp41, and
89.6Pgp140. (B) Development of anti-SHIV-89.6P (top panels) and SHIVSF162P4 (bottom panels) neutralizing antibodies following SHIV-89.6P challenge.
282 R. Xu et al. / Virology 349 (2006) 276–289
283R. Xu et al. / Virology 349 (2006) 276–289Within 4 weeks post-infection, all six SF162gp140-immu-
nized animals developed anti-SHIV-89.6P NAbs (Fig. 3B). In
contrast, only three of six ΔV2gp140-immunized animals
developed such antibodies during the same period. Eight weeks
post-infection, all the SF162gp140 immunized animals and 4/6
ΔV2gp140-immunized animals had robust anti-SHIV-89.6P
NAbs. In contrast to the mock-immunized animals, binding and
NAbs against SHIV89.6P were developed at the same time in the
previously immunized animals, which is consistent with the
notion that immunization with SF162gp140 and ΔV2gp140
proteins ‘primed’ for the development of anti-SHIV89.6P NAbs.
The titers of NAbs against the homologous SHIVSF162P4
virus remained high in all immunized animals following
SHIV-89.6P-infection. Only one of the two mock-immunized
animals with detectable anti-SHIV-89.6P NAbs developed
anti-SHIVSF162P4 NAbs (animal A02186).
Development of cell-mediated anti-viral responses
The mock-immunized animals developed primary cell-
mediated immune responses against the Env and Gag of
SHIV89.6P within 4 weeks post-challenge (Fig. 4A). Although
these responses were detectable throughout the course of
infection, their magnitude was significantly lower than that
recorded in the vaccinated animals. It is interesting to note, that
although the SF162gp140 and ΔV2gp140-immunized animals
very rapidly developed and maintained strong anti-SHIV89.6P
Env cellular responses, the mock-immunized animals did not
developed anti-SHIVSF162P3 Env cellular responses. Therefore,
prior immunization with SF162-derived Env immunogens more
efficiently primed for the development of anti-89.6P Env
cellular responses, which were boosted following infection with
SHIV-89.6P. Similarly to what we recorded during immuniza-
tion, no difference in the potency of cell-mediated responses
between the SF162gp140 and ΔV2gp140 immunized animals
was recorded following infection. Overall, our data suggest that
both cell-mediated responses and neutralizing antibodies
participated in controlling replication of SHIV89.6P.
Discussion
In the absence of a vaccine that would elicit anti-viral
immune responses capable of offering sterilizing immunity
against HIV, it may be imperative to design immunogens and
develop immunization protocols that will facilitate the gener-
ation upon infection of anti-viral responses that will control
viral replication for extended periods of time. Key to the
development of such immunization protocols is the induction of
strong and long-lived immunological T and B cell memory
responses to multiple viral antigens. It is believed that this will
lead to the development of accelerated effector responses upon
infection and result to the effective and long lasting control of
infection.
Previously, we reported that the antibody responses elicited
in macaques by two HIV-1 Env proteins, SF162gp140 and
ΔV2gp140, can effectively reduce viral replication of the
homologous SHIV, SHIVSF162P4 (Buckner et al., 2004). In the
present study, we aimed at examining whether a similarreduction in viral replication will be recorded during heterol-
ogous SHIV challenge. To this end, we used SHIV89.6P as a
challenge virus. Concerns were raised about the use of this X4-
tropic virus to examine HIV-1 Env-related pathogenic events in
monkeys because it very rapidly depletes peripheral CD4+ T
lymphocytes (something that does not occur frequently during
HIV infection of humans) and because it is considered to be
relatively easy to neutralize by antibodies (Feinberg and Moore,
2002). However, SHIV-89.6P is the best characterized SHIV
and thus we thought we could compare our results to those
obtained by others. In addition, protection from SHIV-89.6P-
infection by active immunization has yet to be reported and the
virus can easily escape neutralization by single amino acid
changes (Etemad-Moghadam et al., 1998), which highlights the
difficulty in vaccinating against this virus during heterologous
challenge. There is approximately 80% amino acid homology
between the envelope of SHIV-89.6P and our Env immunogens,
thus making it a valid heterologous challenge virus.
A total of twelve animals were immunized with SIVgag
derived from SIVmac239, which is the same antigen expressed
by SHIV89.6P. In accordance with results from numerous
previous studies, DNA-immunization elicited cell-mediated
responses against this viral antigen in all animals, but the
magnitude of the responses was variable among the animals
(Casimiro et al., 2003). In addition to SIVGag, the animals were
immunized with HIV-1 Env-derived immunogens, either
SF162gp140 or ΔV2gp140. The anti-Gag cell-responses were
more potent than the anti-Env responses during the DNA phase
of immunization (Fig. 1C). Following the immunization with
recombinant Env proteins, the anti-Env cell-mediated responses
became more potent than the anti-Gag responses in most
animals. Potentially, these results indicate that immunization
with recombinant proteins and with DNA vectors expressing
these proteins may enhance the anti-protein cell-mediated
responses. We did not observe differences in the ability of
Mamu-A*01+ and Mamu-A*01- animals to elicit anti-Gag or
anti-Env cell-mediated responses during immunization.
Although we did not record differences in the abilities of the
SF162gp140 and ΔV2gp140 proteins to elicit cell-mediated
responses, differences were recorded in their abilities to elicit
antibodies. During the DNA phase of immunization although all
the animals in the SF162gp140 immunized group developed
homologous anti-gp120-binding antibodies, only half of the
animals in the ΔV2gp140-immunized group developed (tran-
siently) such antibodies (Fig. 1A). These differences could be
due to in vivo differences in expression of these two proteins,
although in vitro expression studies indicate that both
SF162gp140 and ΔV2gp140 proteins are similarly expressed
(Stamatatos et al., 2000). Interestingly, during this period,
antibodies against the heterologous 89.6Pgp140 or HxB2gp41
Env proteins were undetectable in both groups.
Following the first protein-boosting all immunized animals
except one animal in the ΔV2gp140 group developed
homologous anti-gp120 binding antibodies (Fig. 1A). Not all
the animals developed anti-89.6Pgp140 or anti-HxB2gp41
binding antibodies during this time, and the titers of such
antibodies decreased to undetectable levels. These results
Fig. 4. IFN-γ ELISPOT responses following SHIV-89.6P-challenge. (A) Secretion of IFN-γ following stimulation of PBMCs with SHIV-89.6P Env (top panel),
SIVmac239 Gag (center panel) and SHIVSF162P3 Env (bottom panel) peptides. (B) Sum of INF-γ ELISPOT responses to SHIV-89.6P Env and SIVmac239 Gag.
PBMCs were isolated on challenge day (▪), 1 week ( ), 3 or 4 weeks ( ), 8 weeks ( ), 16 weeks (□) and 52 weeks ( ) after challenge. * Not available samples. (+)
MamuA*01+ animals.
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285R. Xu et al. / Virology 349 (2006) 276–289suggest that our immunization protocol did not elicit the
generation of high numbers of memory B cells that secrete
antibodies against these heterologous Env proteins. Following
the second immunization with recombinant Env more animals
in each group developed homologous and heterologous anti-
Env binding antibodies.
In accordance with our previous studies (Buckner et al.,
2004), both immunogens elicited strong homologous NAbs.
They also elicited NAbs against heterologous HIV-1 isolates,
including certain primary isolates. However, the laboratory
adapted isolates tested here (MN and NL4-3) were significantly
more susceptible to neutralization than any of the primary
isolates tested. Some primary isolates (3988 and 7165) were
susceptible to neutralization by most sera tested, while others
(like AR29 and BG1168, and others like: JRCSF, 92US712 and
92HT594, not shown) were either resistant to all sera tested or
susceptible to only a minority of sera tested.
In contrast to our previous observations (Barnett et al.,
2001), in this study, we did not record differences in the
abilities of SF162gp140 and ΔV2gp140 to elicit heterologous
NAbs against primary isolates. Unfortunately sera from that
earlier study are no longer available for a side-by-side
comparison of the neutralizing activity of the previous and
current sera. Several possible explanations could account for
the apparent discrepancy in our results. Previously, the
neutralization assays were conducted with replication compe-
tent viruses produced in human PBMCs and PBMCs as target
cells. In the present study, we used single round competent
viruses produced in 293T cells and TZM-bl cells as target
cells during neutralization. The ability of certain anti-HIV
NAbs to neutralize a particular isolate appears to depend on
the type of cells used as a target during the neutralization
experiments (Binley et al., 2004). The SF162gp140 and
ΔV2gp140 elicit antibodies that differentially recognize the
various HIV envelope target domains (Srivastava et al.,
2003b), an indication that they elicit antibodies with different
epitope-specificities, however, their overall potentials to
neutralize the homologous virus are very similar. Differences
in their abilities to elicit neutralizing antibodies against
heterologous isolates may not be evident when the target
cell is not PBMC, especially since the titers of cross-reactive
NAbs elicited by our immunogens (both in the previous and
current study) were weak. Overall however, our previous and
present observations are in general agreement that the
SF162gp140 and ΔV2gp140 immunogens elicit sporadic
and weak heterologous NAbs against primary HIV-1 isolates.
We anticipate therefore that immunization with these two
proteins would have reduced viral replication during acute
infection (and potentially prevent infection) if the challenge
viruses expressed envelopes similar to those of MN and NL4-
3, but not those expressed by the other heterologous viruses
tested here.
Detectable, but sporadic and weak anti-Gag and anti-Env
cell-mediated responses were detectable following infection in
the mock-immunized animals. In contrast, significantly more
potent cell-mediated anti-viral responses were elicited in the
immunized animals. In agreement with previous other studies,infection resulted in the boosting of vaccine elicited cell-
mediated anti-SIVGag responses (Amara et al., 2002b;
Barouch et al., 2000), but also of anti-Env targeted cellular
responses. Interestingly, anti-SF162 Env cell-mediated
responses were maintained following SHIV-89.6P challenge
in all vaccinated animals, while the mock-immunized animals
never developed such responses. Thus, prior immunization
with SF162 derived Env allows the development following
infection of cross-reactive anti-89.6P Env cell-mediated
responses.
Several groups have reported on the important protective
role that cell-mediated responses play in controlling SHIV89.6P
replication (Amara et al., 2001; Barouch et al., 2000, 2001; Seth
et al., 2000). Our studies support those observations, since the
two animals in the ΔV2gp140 immunized group (A02183 and
A02185) that died of AIDS were the two animals of this group
that did not develop strong cell-mediated antiviral responses
(Table 3).
Neutralizing antibody responses, are also important for the
efficient control of SHIV89.6P replication (Amara et al., 2002a;
Barouch et al., 2001; Rasmussen et al., 2002). The two mock
immunized animals (A02180 and A00051) that developed anti-
SHIV-89.6P NAbs within 8 weeks post-infection (Fig. 3B),
were the two animals of this group that contained viral
replication and had stable CD4+ T lymphocyte numbers in the
periphery. Interestingly, prior immunization with the
SF162gp140 protein accelerated the development of anti-
SHIV89.6P NAbs in all six animals of this group. Importantly,
immunization with SF162gp140 was more effective in eliciting
anti-SHIV-89.6P NAbs following infection than immunization
with ΔV2gp140. Although the anti-SHIV-89.6P neutralizing
antibody responses were undetectable during immunization we
believe that immunization with SF162gp140 more effectively
primed for the development of anti-SHIV89.6P NAbs than
immunization with ΔV2gp140. Deletion of the V2 loop from
the SF162gp140 background alters the immunogenic properties
of the remaining regions, in particular that of the V3 loop
(Srivastava et al., 2003b). Major neutralizing determinants on
the SHIV89.6P envelope are located on the V3 and V2 loops
(Etemad-Moghadam et al., 1998). Thus, the absence of the V2
loop and the alteration of the immunogenic properties of the V3
loop on the ΔV2gp140 immunogen may render it less effective
in eliciting NAbs against isolates with the same neutralization
profiles as SHIV89.6P.
Overall, our results indicate that differences in the structure
and immunogenic properties of HIV envelope immunogens can
affect the development of NAbs following infection and




The isolation and phenotypic characterization of the
SHIV89.6P, SHIVSF162P4 were previously reported (Harouse et
al., 1999; Reimann et al., 1996).
Table 3













NAb titer Peak IFN-γ secretion a
(SFC/106 PBMC)
Acute b Chronic c
P4 89.6P Env Gag PIw4 SHIV PIw8 SHIV Env Gag
89.6P P4 89.6p P4 89.6p
A02194 −/− −/− −/− −/− −/− −/− −/− 15 88 8 6.7 5.3
A02190 −/− −/− −/− −/− −/− −/− −/− −/− 14 −/− 7.0 4.9
A02180 −/− −/− −/− −/− 34 140 200 12 115 198 6.8 3.2
O2181 −/− −/− −/− −/− −/− −/− −/− −/− 43 188 6.7 5.1
A00051 −/− −/− −/− −/− −/− −/− 68 27 96 88 6.7 2.1
A02189 SF162 >3000 −/− 890 400 66 565 744 69 243 1441 6.0 2.1
A02188 SF162 >3000 −/− 405 130 24 1800 20 850 1190 486 6.3 3.3
A02186 SF162 410 −/− 240 173 13 1450 66 −/− 78 274 6.3 5.1
A02179 SF162 >3000 −/− 500 258 13 2200 35 362 624 2479 5.9 2.2
O2193 SF162 1800 −/− 188 33 16 480 125 328 407 243 5.7 2.2
A02177 SF162 410 −/− 550 835 1200 810 2000 880 600 1563 6.7 2.6
A02185 ΔV2 2000 −/− 308 640 38 −/− 108 49 6.8
A02183 ΔV2 760 −/− 1113 203 −/− 470 −/− −/− 35 −/− 6.6 5.2
O2184 ΔV2 445 −/− 724 143 −/− 350 35 1008 796 100 5.6 2.0
O2187 ΔV2 600 −/− 113 273 70 474 1000 458 785 1081 6.5 4.3
A02311 ΔV2 1700 −/− 213 230 −/− 620 22 217 670 1255 6.7 4.5
A02178 ΔV2 1000 −/− 303 28 148 1500 250 165 1466 230 6.7 3.2
a Peak IFN-γ secretion recorded at 3 or 4 weeks post-challenge.
b Peak plasma RNA viral load during acute infection (2 weeks post-challenge).
c Mean plasma RNA viral load during chronic infection (week 8 through week 52 post-challenge).
286 R. Xu et al. / Virology 349 (2006) 276–289Immunizations and viral-challenge
Seventeen rhesus macaques of Indian origin were divided
into three experiment groups: Group 1 (N = 5): mock-
immunized; Group 2 (N = 6): SIV Gag p55 and HIV-
1SF162gp140 Envelope; and Group 3 (N = 6): SIV Gag
p55 and HIV-1SF162ΔV2 gp140. The generation and
characterization of these two HIV Envelope immunogens
was reported previously (Barnett et al., 2001; Srivastava et
al., 2003a, 2003b). The animals were immunized intramus-
cularly and intradermally at weeks 0, 4, 9 with DNA vectors
expressing these immunogens (2 mg of each vector) as we
previously described in detail (Barnett et al., 2001). The
DNA-encoded SIV gag and HIV envelope sequences were
codon-optimized. Mock-immunized animals received the
empty DNA plasmid vector. On weeks 30 and 50, the animals
in Groups 2 and 3 were immunized again with DNAvectors and
at the same time with 0.1 mg of recombinant, CHO-produced,
soluble trimeric gp140 envelope proteins mixed with MF-59C
adjuvant (Chiron Co. Emeryville, CA) intramuscularly. We term
this DNA plus recombinant protein immunization step as
‘recombinant protein boost' for simplicity. The animals that
were immunized with DNA vectors expressing SF162gp140
received the SF162gp140 recombinant protein and those
animals immunized with DNA vectors expressing
ΔV2gp140 received the ΔV2gp140 recombinant protein.
The mock-immunized animals received the empty vector andMF59C adjuvant. For simplicity we will refer to the animal
immunized with SF162gp140 and SIVgag, as SF162-
immunized, and those immunized with the ΔV2gp140 and
SIVgag, as ΔV2-immunized. Two weeks following the last
immunization, all animals were challenged intravenously
with 100 TCID50 of a cell-free stock of the SHIV-89.6P
virus. The Mamu-A*01 status of these animals was
determined as recently described (Seaman et al., 2005).
Determination of binding anti-Env antibodies
The development of anti-HIV Envelope-specific binding
antibodies were quantified during immunization and following
infection by enzyme-linked immunosorbent assay (ELISA) as
described previously (Barnett et al., 2001; Buckner et al., 2004).
Briefly, 96-well ELISA plates (Immulon 2HB; Thermo
Electron, FL) were coated over night with purified soluble
oligomeric KB9gp140 (kindly provided from Shiu-Lok Hu,
UW), SF162gp120 (Chiron Co. Emeryville, CA) or HXB2gp41
(Viral Therapeutics, Inc., Ithaca, NY) protein (0.05 μg of
protein in 0.1 ml of 100 mM NaHCO3, PH 9) at room
temperature, then blocked with SuperBlock (SB) (Pierce,
Rockford, IL). Heat-inactivated (56 °C for 1 h) plasma collected
from the animals at various stages of immunization and
infection was serially diluted in Tris-buffered saline (TBS)
(25 mM Tris-144 mM NaCl [pH 7.6]) containing 10%
SuperBlock (SB) and 0.03% Tween-20 and added to the wells
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plasma from the corresponding animals was used as negative
control. The Env-bound antibodies were detected with the use
of a goat anti-human immunoglobulin IgG coupled to alkaline
phosphatase (Zymed Immunochemicals, South San Francisco,
CA) (1:30,000 dilution in TBS containing 10% SB and 0.03%
Tween-20) (2-h incubation at room temperature). Substrate for
alkaline phosphatase (DAKOCytomation, Carpinteria, CA) was
added (0.05 ml per well) for 1 h at room temperature. Following
the addition of amplifier the optical density at 490 nm (OD490)
from each well were recorded on a Vmax microplate reader
(Molecular Devices, Sunnyvale, CA). A plot of the OD490
signals versus plasma dilutions was generated, and end-point
antibody titers were determined as the highest post-immuniza-
tion (or post-viral challenge) plasma dilution that produces an
OD490 signal twice (in case of gp120) and three times (in case of
gp140 and gp41) that of the corresponding pre-immunization
plasma at the lowest dilution tested.
Neutralization assays
Plasma samples were assayed for neutralizing activity against
homologous (SHIVSF162P4) and heterologous (SHIV89.6P)
SHIVs and several HIV-1 primary viruses isolated early
following infection (3988, 6101, AR29, QH0515, QH0692,
TRO, SS168, BG1168, 6535, 7165, PVO) (Bures et al., 2000;
Montefiori et al., 2003; Pilgrim et al., 1997) neutralizing activity
using TZM-bl cell line as target cells (Herrera et al., 2003).
7 × 103 TZM-bl cells were plated in 96 well tissue culture plates
(Costar, Corning Inc. Corning, NY) and cultured overnight in
DMEM supplemented with 10% fetal calf serum (FCS). Viruses
(56TCID50) in 28 μl of complete DMEM media were pre-
incubated for 1.5 h at 37 °C in 96-well U-bottom plates (Falcon,
Becton Dickinson, Franklin Lakes, NJ) with an equal volume of
serially diluted heat-inactivated (56 °C for 1 h) plasma collected
from the animals at various stage of immunization or infection.
For each plasma dilution, triplicate wells were used. 50 μl of
virus and plasma mixture were then added to polybrene
pretreated TZM-bl cells together with 50 μl of complete
DMEM media. Cells were incubated at 37 °C for 3 days and
cell-associated luciferase expression was then determined, as
previously described (McCaffrey et al., 2004). Themean percent
neutralization and the standard deviation from triplicate wells for
each post-immunization (or infection) plasma dilution was
calculated based on the luciferase activity recorded in wells
containing the corresponding pre-immunization plasma at the
same dilution. As a negative control, cells were incubated in the
absence of virus, and as a positive control cells were incubated
with virus in the absence of macaque plasma. Additional
neutralization assays against HIV-1 viruses isolated during the
chronic phase of infection were performed at Virologic Inc, as
previously described (Richman et al., 2003).
INF-γ ELISPOT
The number of antigen-specific IFN-γ-secreting cells was
determined by ELISPOT assay using the Ucytech kit (Ucytech,Utrecht, The Netherlands) according to the manufacturer's
instructions. Briefly, over night cultured cryopreserved PBMCs
(2 × 105) were mixed with HIV Env or SIV Gag peptides and
added to duplicate wells coated with an anti-IFN-γ antibody.
Individual peptide pools covered the entire SIVmac239 Gag
(125 peptides), SHIV-89.6P Env (86 peptides), or SHIVSF162P3
Env (211 peptides). Each pool comprised 15-aa peptides
overlapping by 11 aa, except for the SHIV89.6P Env pool,
which comprised 20-aa peptides overlapping by 10 aa. Each
peptide pool was divided into 2 groups containing the same
number of peptides. The final concentration of each peptide
was 1 μg/ml when incubated with the cells. As a negative
control we used medium with 0.06% DMSO (same concen-
tration as in the peptide group medium), and as a positive
control we used SEB (1 μg/ml). Following a 24-h incubation
period at 37 °C, the plates were washed once with distilled
water and nine times with PBS containing 0.05% Tween-20
(PBST). Biotinylated detector anti-IFN-γ antibody was added
for 1 h at 37 °C. The wells were washed ten times with PBST,
and incubated with 0.05 ml of GABA antibody for 1 h at 37
°C. After washing with PBST (ten times), the plates were
developed with 0.03 ml of developer for approximately 15 min
at room temperature, and the reaction was stopped by washing
the wells with tap water. The plates were air-dried and the
number of spot-forming cells (SFC) per well was determined
with a Bioreader 3000 (BioSys Inc., Montgomery Village,
MD). The number of SFC per 106 PBMCs was calculated
using the following formula: (Number of SFC in unknown
wells −2× the number of SFC in negative wells) ×5. The only
samples considered positive were those that showed >10 SFC.
When the number of SFC in the negative control wells was less
than 5, 10 spots were subtracted from the corresponding
unknown wells.
Peripheral CD4+- and CD8+- T- lymphocyte counts
0.025 ml of whole blood was placed in a polypropylene tube
and incubated at room temperature for 1 h with a cocktail of
three monoclonal antibodies: PE-anti-CD4 (clone M-T477, BD-
PharMingen, San Diego, CA), FITC-anti-CD3 (clone SP34,
BD-PharMingen) and PC5-anti-CD8 (clone B9.11, Immuno-
tech, France). Red blood cells were lysed with 0.5 ml of
Versalyse (Beckman Coulter, Marseille, France), and the
absolute numbers CD3+CD4+ and CD3+CD8+ T cells were
determined on a Coulter Epics XL.MCL flow-cytometer
(Coulter Corporation, Miami, FL).
Plasma viral load determination
QC-PCR (lower limit of detection is 50 RNA copies per ml)
(Mooij et al., 2000; ten Haaft et al., 2001; Ten Haaft et al., 1998)
was used for quantitating SIV RNA in their plasma for the first
28 weeks post challenge. The branched-chain DNA amplifica-
tion assay (Bayer Reference Testing Laboratory, Emeryville,
CA) (lower limit of detection is 125 SHIV RNA copies per ml)
was employed to quantify plasma SHIV RNA copy numbers
after that time point.
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